2018 Clinical Trials Epilepsy Programs 
MedicalJane
OCTOBER 3, 2019
The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.
Puff Puff Post
OCTOBER 3, 2019
Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 19, 2021
While many countries around the world have legalized or decriminalized cannabis or have eased up on enforcement in recent years, in Japan in 2018 there was a sharp increase in cannabis-related arrests — and 80% of them were possession charges. of Japanese have reported consuming cannabis, as opposed to more than 40% in the US and Canada.
MGC Pharma
FEBRUARY 20, 2018
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
MedicalJane
JUNE 29, 2018
The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.
Puff Puff Post
OCTOBER 3, 2019
Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.
Veriheal
AUGUST 31, 2020
Program between St. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. She is entering the 8-year Dual Admit B.S./M.D. Bonaventure University and George Washington University School of Medicine. .
Expert insights. Personalized for you.
74 
Let's personalize your content